首页> 外国专利> ONCOLYTIC VIRUS (ONCOLYTIC IMMUNOTHERAPY) CAPABLE OF EFFECTIVELY TREATING EVEN METASTATIC CANCER WHILE ENSURING SAFETY, WITH EXPRESSION CONTROL SYSTEM PROVIDING OPTIMAL EXPRESSION LEVEL OF MOUNTED IMMUNOGENIC GENE

ONCOLYTIC VIRUS (ONCOLYTIC IMMUNOTHERAPY) CAPABLE OF EFFECTIVELY TREATING EVEN METASTATIC CANCER WHILE ENSURING SAFETY, WITH EXPRESSION CONTROL SYSTEM PROVIDING OPTIMAL EXPRESSION LEVEL OF MOUNTED IMMUNOGENIC GENE

机译:能够在确保安全的同时有效治疗甚至转移性癌症的溶瘤病毒(溶瘤免疫疗法),其表达控制系统可提供固定的免疫原基因的最佳表达水平

摘要

The present invention is based on a novel concept for finding the optimum expression level of a therapeutic gene for inducing the largest therapeutic effect without any adverse reaction. An object of the present invention is to develop an immuno-viral therapeutic vector exerting the optimal therapeutic effect while ensuring high safety. The present invention provides, for example, an oncolytic virus comprising an immunity-inducing gene operably linked to the downstream of E2F promoter or a promoter having an activity equivalent thereto, wherein at least one promoter for nucleic acids encoding an element essential for viral replication or assembly is replaced with a promoter for an organ specific highly expressed factor or with a promoter for a cancer cell specific highly expressed factor.
机译:本发明基于一种新颖的概念,用于寻找治疗基因的最佳表达水平,以诱导最大的治疗效果而没有任何不良反应。本发明的目的是开发一种在确保高安全性的同时发挥最佳治疗效果的免疫病毒治疗载体。本发明提供例如溶瘤病毒,其包含可操作地连接至E2F启动子的下游或具有与其等效活性的启动子的免疫诱导基因,其中至少一个用于编码病毒复制或启动子必需元件的核酸的启动子。用器官特异性高表达因子的启动子或癌细胞特异性高表达因子的启动子代替装配体。

著录项

  • 公开/公告号EP3708657A1

    专利类型

  • 公开/公告日2020-09-16

    原文格式PDF

  • 申请/专利权人 KAGOSHIMA UNIVERSITY;

    申请/专利号EP20180875645

  • 发明设计人 KOSAI KEN-ICHIRO;IJICHI NOBUHIRO;

    申请日2018-11-08

  • 分类号C12N7/01;A61K35/761;A61K47/55;A61K48;A61P35;A61P35/04;A61P37/04;A61P43;C12N15/861;

  • 国家 EP

  • 入库时间 2022-08-21 11:40:51

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号